Person · CIK 1798679

Masaru Matsuda

EVP at Arcutis Biotherapeutics

Earlier: Halozyme Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$4.9M

Noticed on Form 144$2.9M

Bought on Form 4$19K

Companies2

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Arcutis Biotherapeutics ARQT	Common Stock	Directly	111,289	Nov 4, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQT	Stock Option (right to buy) exercise $3.64, expires Jan 12, 2034, into Common Stock	Directly	136,000	Nov 4, 2026 · Filing · EDGAR
Halozyme Therapeutics	Common Stock	Directly	20,049	Sep 4, 2021 · Filing · EDGAR
Halozyme Therapeutics	Restricted Stock Units into Common Stock	Directly	6,883	Sep 4, 2021 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2026	$1.4M	Not machine-readable	—
Q3 2026	$374K	Not machine-readable	—
Q2 2026	$192K	Not machine-readable	—
Q1 2026	$1.3M	$1.3M	—
Q4 2025	$300K	$300K	—
Q3 2025	$674K	$674K	—
Q2 2025	$101K	$101K	—
Q1 2025	$148K	$284K	—
Q4 2024	$61K	$61K	$12K
Q3 2024	$47K	$47K	—
Q2 2024	$60K	$60K	$7K
Q1 2024	$42K	$42K	—
Q4 2023	$4K	$4K	—
Q2 2023	$14K	$14K	—
Q1 2023	$23K	Not machine-readable	—
Q4 2022	$31K	Not machine-readable	—
Q2 2022	$35K	Not machine-readable	—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Arcutis Biotherapeutics ARQT · Merrill Lynch · 10b5-1 plan adopted Jun 6, 2025 · 2 notices
Mar 2, 2026	12,058 · ~$314K	Mar 2, 2026	Partly sold Sold 11,865 in 3 sales, Feb 27 to Mar 2 · $309K likely match Form 4	Filing · EDGAR
Dec 1, 2025	1,657 · ~$50K	Dec 1, 2025	Sold as noticed Sold 1,657 at $30.23 on Dec 1 · $50K Form 4	Filing · EDGAR
Arcutis Biotherapeutics ARQT · Merrill Lynch · 10b5-1 plan adopted Jun 5, 2025 · 1 notice
Feb 2, 2026	40,638 · ~$1M	Feb 2, 2026	Sold as noticed Sold 40,831 in 5 sales, Feb 2 to Mar 2 · $1M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Arcutis Biotherapeutics ARQT · Merrill Lynch · No 10b5-1 plan stated · 2 notices
Nov 19, 2025	2,550 · ~$72K	Nov 19, 2025	Sold as noticed Sold 2,550 in 2 sales, Nov 19 to Nov 19 · $72K Form 4	Filing · EDGAR
Nov 3, 2025	7,208 · ~$178K	Nov 3, 2025	Sold as noticed Sold 7,165 at $24.71 on Nov 3 · $177K Form 4	Filing · EDGAR
Arcutis Biotherapeutics ARQT · Merrill · 10b5-1 plan adopted Jun 5, 2025 · 1 notice
Sep 4, 2025	36,130 · ~$584K	Sep 4, 2025	Sold as noticed Sold 36,173 in 2 sales, Sep 4 to Nov 3 · $585K Form 4 (1) · Form 4 (2)	Filing · EDGAR
Arcutis Biotherapeutics ARQT · Merrill · No 10b5-1 plan stated · 13 notices
Aug 4, 2025	6,330 · ~$91K	Aug 4, 2025	Sold as noticed Sold 6,330 at $14.33 on Aug 4 · $91K Form 4	Filing · EDGAR
May 28, 2025	1,800 · ~$25K	May 28, 2025	Sold as noticed Sold 1,800 at $13.78 on May 28 · $25K Form 4	Filing · EDGAR
May 2, 2025	5,030 · ~$76K	May 2, 2025	Sold as noticed Sold 5,030 at $15.20 on May 2 · $76K Form 4	Filing · EDGAR
Mar 3, 2025	3,263 · ~$43K	Mar 3, 2025	Sold as noticed Sold 3,263 at $13.03 on Mar 3 · $43K Form 4	Filing · EDGAR
Feb 3, 2025	8,338 · ~$242K	Feb 3, 2025	Sold as noticed Sold 8,338 at $12.70 on Feb 3 · $106K Form 4	Filing · EDGAR
Nov 19, 2024	1,775 · ~$17K	Nov 19, 2024	Sold as noticed Sold 1,775 at $9.68 on Nov 19 · $17K Form 4	Filing · EDGAR
Nov 4, 2024	5,015 · ~$44K	Nov 4, 2024	Sold as noticed Sold 5,015 at $8.68 on Nov 4 · $44K Form 4	Filing · EDGAR
Aug 2, 2024	5,220 · ~$47K	Aug 2, 2024	Sold as noticed Sold 5,220 at $9.02 on Aug 2 · $47K Form 4	Filing · EDGAR
May 28, 2024	1,775 · ~$16K	May 28, 2024	Sold as noticed Sold 1,775 at $9.01 on May 28 · $16K Form 4	Filing · EDGAR
May 2, 2024	5,016 · ~$44K	May 2, 2024	Sold as noticed Sold 5,016 at $8.74 on May 2 · $44K Form 4	Filing · EDGAR
Mar 4, 2024	3,760 · ~$42K	Mar 4, 2024	Sold as noticed Sold 3,760 at $11.12 on Mar 4 · $42K Form 4	Filing · EDGAR
Nov 21, 2023	1,850 · ~$4K	Nov 21, 2023	Sold as noticed Sold 1,850 at $1.98 on Nov 21 · $4K Form 4	Filing · EDGAR
May 31, 2023	1,830 · ~$14K	May 31, 2023	Sold as noticed Sold 1,830 at $7.80 on May 31 · $14K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 11 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Arcutis Biotherapeutics (ARQT): Sold 40,000 at $34.32 on Nov 4, 2026 · $1.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Arcutis Biotherapeutics (ARQT): Sold 1,219 at $31.86 on Nov 2, 2026 · $39K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Arcutis Biotherapeutics (ARQT): Sold 3,674 at $25.00 on Sep 16, 2026 · $92K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Arcutis Biotherapeutics (ARQT): Sold 9,989 at $25.03 on Sep 8, 2026 · $250K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Arcutis Biotherapeutics (ARQT): Sold 1,230 at $26.12 on Aug 3, 2026 · $32K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Arcutis Biotherapeutics (ARQT): Sold 884 at $23.61 on May 4, 2026 · $21K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Arcutis Biotherapeutics (ARQT): Sold 7,372 at $23.27 on May 4, 2026 · $172K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics (ARQT): Sold 18 at $16.52 on Mar 2, 2023 · $297 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics (ARQT): Sold 1,416 at $15.82 on Mar 2, 2023 · $22K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics (ARQT): Sold 1,720 at $18.19 on Nov 21, 2022 · $31K	Filing · EDGAR
—	—	—	Notice not machine-readable Arcutis Biotherapeutics (ARQT): Sold 1,795 at $19.73 on Jun 2, 2022 · $35K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Arcutis Biotherapeutics ARQT EVP, Chief Legal Officer · filings 2022 to 2026 · sold $4.9M · bought $19K · $2.9M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 4, 2026	Option or RSU exercised or converted	+40,000	$3.64	$146K	151,289 direct	Filing · EDGAR
Nov 4, 2026	Sale under a 10b5-1 plan	−40,000	$34.32	$1.4M	111,289 direct	Filing · EDGAR
Nov 4, 2026	Option or RSU exercised or converted Stock Option (right to buy)	−40,000			136,000 direct	Filing · EDGAR
Nov 2, 2026	Sale under a 10b5-1 plan	−1,219	$31.86	$39K	111,289 direct	Filing · EDGAR
Sep 16, 2026	Sale under a 10b5-1 plan	−3,674	$25.00	$92K	112,508 direct	Filing · EDGAR
Sep 8, 2026	Sale under a 10b5-1 plan	−9,989	$25.03	$250K	116,182 direct	Filing · EDGAR
Aug 3, 2026	Sale under a 10b5-1 plan	−1,230	$26.12	$32K	126,171 direct	Filing · EDGAR
May 4, 2026	Sale under a 10b5-1 plan	−7,372	$23.27	$172K	127,573 direct	Filing · EDGAR
May 4, 2026	Sale under a 10b5-1 plan	−884	$23.61	$21K	126,689 direct	Filing · EDGAR
Mar 2, 2026	Sale under a 10b5-1 plan	−6,553	$25.16	$165K	137,125 direct	Filing · EDGAR
Mar 2, 2026	Sale under a 10b5-1 plan	−193	$25.91	$5K	136,932 direct	Filing · EDGAR
Mar 2, 2026	Sale under a 10b5-1 plan	−1,987	$25.70	$51K	136,932 direct	Filing · EDGAR
Feb 27, 2026	Grant or award from the company	+37,000			147,003 direct	Filing · EDGAR
Feb 27, 2026	Sale under a 10b5-1 plan	−3,325	$27.95	$93K	143,678 direct	Filing · EDGAR
Feb 27, 2026	Grant or award from the company Stock Option (right to buy)	+97,000			97,000 direct	Filing · EDGAR
Feb 2, 2026	Sale under a 10b5-1 plan	−7,983	$25.50	$204K	142,658 direct	Filing · EDGAR
Feb 2, 2026	Sale under a 10b5-1 plan	−8,562	$24.97	$214K	134,096 direct	Filing · EDGAR
Feb 2, 2026	Sale under a 10b5-1 plan	−19,379	$25.24	$489K	114,717 direct	Filing · EDGAR
Feb 2, 2026	Sale under a 10b5-1 plan	−4,714	$25.63	$121K	110,003 direct	Filing · EDGAR
Dec 1, 2025	Sale under a 10b5-1 plan	−1,657	$30.23	$50K	150,641 direct	Filing · EDGAR
Nov 19, 2025	Sale under a 10b5-1 plan	−989	$27.95	$28K	153,037 direct	Filing · EDGAR
Nov 19, 2025	Sale under a 10b5-1 plan	−1,561	$28.50	$44K	151,476 direct	Filing · EDGAR
Nov 3, 2025	Sale under a 10b5-1 plan	−7,165	$24.71	$177K	154,069 direct	Filing · EDGAR
Nov 3, 2025	Sale under a 10b5-1 plan	−43	$25.40	$1K	154,026 direct	Filing · EDGAR
Sep 4, 2025	Sale under a 10b5-1 plan	−36,130	$16.16	$584K	161,234 direct	Filing · EDGAR
Aug 4, 2025	Sale under a 10b5-1 plan	−6,330	$14.33	$91K	197,364 direct	Filing · EDGAR
May 28, 2025	Sale under a 10b5-1 plan	−1,800	$13.78	$25K	202,599 direct	Filing · EDGAR
May 2, 2025	Sale under a 10b5-1 plan	−5,030	$15.20	$76K	204,399 direct	Filing · EDGAR
Mar 3, 2025	Sale under a 10b5-1 plan	−3,263	$13.03	$43K	209,429 direct	Filing · EDGAR
Feb 28, 2025	Grant or award from the company	+34,000			212,692 direct	Filing · EDGAR
Feb 28, 2025	Grant or award from the company Stock Option (right to buy)	+89,000			89,000 direct	Filing · EDGAR
Feb 3, 2025	Sale under a 10b5-1 plan	−8,338	$12.70	$106K	178,692 direct	Filing · EDGAR
Nov 30, 2024	Open-market or private purchase	+1,657	$7.11	$12K	187,030 direct	Filing · EDGAR
Nov 19, 2024	Sale under a 10b5-1 plan	−1,775	$9.68	$17K	181,373 direct	Filing · EDGAR
Nov 18, 2024	Grant or award from the company	+4,875			183,148 direct	Filing · EDGAR
Nov 4, 2024	Sale under a 10b5-1 plan	−5,015	$8.68	$44K	178,273 direct	Filing · EDGAR
Aug 2, 2024	Sale under a 10b5-1 plan	−5,220	$9.02	$47K	183,288 direct	Filing · EDGAR
May 31, 2024	Open-market or private purchase	+4,000	$1.69	$7K	185,373 direct	Filing · EDGAR
May 28, 2024	Sale under a 10b5-1 plan	−1,775	$9.01	$16K	188,508 direct	Filing · EDGAR
May 27, 2024	Grant or award from the company	+4,875			190,283 direct	Filing · EDGAR
May 2, 2024	Sale under a 10b5-1 plan	−5,016	$8.74	$44K	185,408 direct	Filing · EDGAR
Mar 4, 2024	Sale under a 10b5-1 plan	−3,760	$11.12	$42K	190,424 direct	Filing · EDGAR
Feb 13, 2024	Grant or award from the company	+74,000			148,634 direct	Filing · EDGAR
Feb 13, 2024	Grant or award from the company	+17,650			166,284 direct	Filing · EDGAR
Feb 13, 2024	Grant or award from the company	+27,900			194,184 direct	Filing · EDGAR
Feb 13, 2024	Returned to the company Stock Option (right to buy)	−185,000			0 direct	Filing · EDGAR
Feb 13, 2024	Returned to the company Stock Option (right to buy)	−35,300			0 direct	Filing · EDGAR
Feb 13, 2024	Returned to the company Stock Option (right to buy)	−55,800			0 direct	Filing · EDGAR
Jan 12, 2024	Grant or award from the company	+28,000			74,634 direct	Filing · EDGAR
Jan 12, 2024	Grant or award from the company Stock Option (right to buy)	+176,000			176,000 direct	Filing · EDGAR
Nov 21, 2023	Open-market or private sale	−1,850	$1.98	$4K	46,634 direct	Filing · EDGAR
Nov 18, 2023	Grant or award from the company	+4,875			48,484 direct	Filing · EDGAR
May 31, 2023	Open-market or private sale	−1,830	$7.80	$14K	42,146 direct	Filing · EDGAR
May 31, 2023	Grant or award from the company	+1,463	$6.38	$9K	43,609 direct	Filing · EDGAR
May 27, 2023	Grant or award from the company	+4,875			43,976 direct	Filing · EDGAR
Mar 2, 2023	Sale under a 10b5-1 plan	−1,416	$15.82	$22K	18,119 direct	Filing · EDGAR
Mar 2, 2023	Sale under a 10b5-1 plan	−18	$16.52	$297	18,101 direct	Filing · EDGAR
Mar 2, 2023	Grant or award from the company	+21,000			39,101 direct	Filing · EDGAR
Mar 2, 2023	Grant or award from the company Stock Option (Right to Buy)	+55,800			55,800 direct	Filing · EDGAR
Nov 21, 2022	Open-market or private sale	−1,720	$18.19	$31K	19,535 direct	Filing · EDGAR

6 earlier transactions are in the filing list below.

Halozyme Therapeutics SVP, General Counsel · filings 2020 to 2021

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 4, 2021	Option or RSU exercised or converted	+6,883			23,461 direct	Filing · EDGAR
Sep 4, 2021	Shares withheld for tax or exercise price	−3,412	$42.22	$144K	20,049 direct	Filing · EDGAR
Sep 4, 2021	Option or RSU exercised or converted Restricted Stock Units	−6,883			6,883 direct	Filing · EDGAR
Feb 15, 2021	Grant or award from the company Option to Purchase Common Stock	+23,311			23,311 direct	Filing · EDGAR
Feb 15, 2021	Grant or award from the company Restricted Stock Units	+13,544			13,544 direct	Filing · EDGAR
Feb 12, 2021	Option or RSU exercised or converted	+4,129			18,625 direct	Filing · EDGAR
Feb 12, 2021	Shares withheld for tax or exercise price	−2,047	$49.84	$102K	16,578 direct	Filing · EDGAR
Feb 12, 2021	Option or RSU exercised or converted Restricted Stock	−4,129			8,258 direct	Filing · EDGAR
Feb 10, 2021	Option or RSU exercised or converted	+6,257			17,699 direct	Filing · EDGAR
Feb 10, 2021	Shares withheld for tax or exercise price	−3,203	$50.60	$162K	14,496 direct	Filing · EDGAR
Feb 10, 2021	Option or RSU exercised or converted Restricted Stock Units	−6,257			18,769 direct	Filing · EDGAR
Sep 4, 2020	Option or RSU exercised or converted	+6,884			13,822 direct	Filing · EDGAR
Sep 4, 2020	Shares withheld for tax or exercise price	−2,380	$27.70	$66K	11,442 direct	Filing · EDGAR
Sep 4, 2020	Option or RSU exercised or converted Restricted Stock Units	−6,884			13,766 direct	Filing · EDGAR
Feb 12, 2020	Option or RSU exercised or converted	+4,130			8,619 direct	Filing · EDGAR
Feb 12, 2020	Shares withheld for tax or exercise price	−1,681	$20.00	$34K	6,938 direct	Filing · EDGAR
Feb 12, 2020	Option or RSU exercised or converted Restricted Stock Units	−4,130			12,387 direct	Filing · EDGAR
Feb 10, 2020	Grant or award from the company Option to Purchase Common Stock	+53,211			53,211 direct	Filing · EDGAR
Feb 10, 2020	Grant or award from the company Restricted Stock Units	+25,026			25,026 direct	Filing · EDGAR

All 64 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Nov 4, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 4, 2026	Form 144	Could not read	EDGAR
Nov 2, 2026	Form 144	Could not read	EDGAR
Sep 18, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Sep 10, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Sep 8, 2026	Form 144	Could not read	EDGAR
Aug 5, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Aug 3, 2026	Form 144	Could not read	EDGAR
May 6, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 4, 2026	Form 144	Could not read	EDGAR
Mar 3, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Mar 2, 2026	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Feb 4, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Feb 2, 2026	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Dec 3, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Dec 1, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 21, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 19, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 5, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 3, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Sep 8, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Sep 4, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Aug 5, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Aug 4, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 29, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 28, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 5, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 2, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Mar 4, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Mar 3, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Feb 4, 2025	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Feb 3, 2025	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Dec 3, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 19, 2024	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 19, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 5, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 4, 2024	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Aug 5, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Aug 2, 2024	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 29, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 28, 2024	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 3, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 2, 2024	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Mar 6, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Mar 4, 2024	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Feb 15, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Jan 17, 2024	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 21, 2023	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 21, 2023	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Jun 2, 2023	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
May 31, 2023	Form 144	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Mar 6, 2023	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Nov 22, 2022	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Jun 2, 2022	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Mar 7, 2022	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Jan 5, 2022	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Jan 5, 2022	Form 3	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Sep 7, 2021	Form 4	Halozyme Therapeutics	Filing · EDGAR
Feb 17, 2021	Form 4	Halozyme Therapeutics	Filing · EDGAR
Feb 12, 2021	Form 4	Halozyme Therapeutics	Filing · EDGAR
Sep 4, 2020	Form 4	Halozyme Therapeutics	Filing · EDGAR
Feb 13, 2020	Form 4	Halozyme Therapeutics	Filing · EDGAR
Feb 12, 2020	Form 4	Halozyme Therapeutics	Filing · EDGAR
Jan 6, 2020	Form 3	Halozyme Therapeutics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 9:49 PM ET. The filing on SEC.gov is the record.